论文部分内容阅读
目的:评价CA153、CA125和VEGF对乳腺癌患者手术前后手术治疗效果以及预后评价的临床意义。方法:收集我院2007年1月到2009年1月乳腺外科收治的女性浸润性导管癌患者131例,比较所有患者术前以及术后3月随访时血清CA153、CA125和VEGF值的变化。结果:四期患者手术前血清CA153、CA125和VEGF亦均高于正常,手术后复查均恢复至正常范围,四组患者手术前后血清CA153、CA125以及VEGF比较差异均有统计学意义(P<0.05),Ⅲ和Ⅳ期血清VEGF、CA125和CA153值均明显高于Ⅰ和Ⅱ期(P<0.05),Ⅰ和Ⅱ期、Ⅲ和Ⅳ期之间血清VEGF、CA125和CA153值比较差异无统计学意义(P>0.05)。结论:CA153、CA125和VEGF检测对于判断乳腺癌的分期有一定作用,能有效评价手术治疗效果判断患者是否复发,以及对肿瘤发展的阶段也具有临床指导意义。
Objective: To evaluate the clinical value of CA153, CA125 and VEGF in the surgical treatment of patients with breast cancer before and after surgery and the prognostic evaluation. Methods: A total of 131 female invasive ductal carcinoma patients admitted to our department from January 2007 to January 2009 were collected. The changes of serum CA153, CA125 and VEGF were compared between preoperative and postoperative follow-up. Results: The levels of serum CA153, CA125 and VEGF before operation in the four patients were also higher than those in normal patients. The levels of serum CA153, CA125 and VEGF in the four groups before and after surgery were all significantly different (P <0.05 ), The serum levels of VEGF, CA125 and CA153 in stage Ⅲ and Ⅳ were significantly higher than those in stage Ⅰ and Ⅱ (P <0.05). There was no significant difference in serum VEGF, CA125 and CA153 between stages Ⅰ and Ⅱ, stage Ⅲ and stage Ⅳ Significance (P> 0.05). Conclusion: The detection of CA153, CA125 and VEGF can play an important role in the staging of breast cancer. It can effectively evaluate the effect of surgical treatment to determine whether patients relapse and have clinical significance in the stage of tumor development.